• 
  Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, Christophe Pomel, Hélène Costaz, et al.. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecologic Oncology, 2022, 167 (1), pp.11-21. ⟨10.1016/j.ygyno.2022.08.005⟩. ⟨hal-03868125⟩
• 
  P. Kubicek, A. L. Cesne, C. Lervat, M. Toulmonde, C. Chevreau, et al.. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC.. BMC Cancer, 2023, BMC Cancer, 23, pp.69. ⟨10.1186/s12885-023-10556-4⟩. ⟨hal-04315885⟩
• 
  Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, et al.. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature Communications, 2024, 15 (1), pp.1985. ⟨10.1038/s41467-024-45974-w⟩. ⟨hal-04549309⟩
• 
  Capucine Baldini, E. Charton, E. Schultz, L. Auroy, A. Italiano, et al.. Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study. ESMO Open, 2022, European Society for Medical Oncology, 7, pp.100468. ⟨10.1016/j.esmoop.2022.100468⟩. ⟨hal-04567217⟩
• 
  M. Brahmi, T. Lesluyes, A. Dufresne, M. Toulmonde, A. Italiano, et al.. Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas.. ESMO Open, 2021, ESMO Open, 6 (1), pp.100037. ⟨10.1016/j.esmoop.2020.100037⟩. ⟨hal-04552489⟩
• 
  Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, Marie Attard, Claire Bournaud, et al.. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131 I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated thyroid Cancer. Clinical Cancer Research, 2023, 29 (13), pp.2401-2409. ⟨10.1158/1078-0432.CCR-23-0046⟩. ⟨inserm-04552345⟩
• 
  Grégoire Marret, Stéphane Temam, Maud Kamal, Caroline Even, Jean-Pierre Delord, et al.. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity. Scientific Reports, 2023, 13, pp.22524. ⟨10.1038/s41598-023-49887-4⟩. ⟨hal-04543900⟩
• 
  P. Sargos, J. Le Guevelou, J. Khalifa, L. Albiges, D. Azria, et al.. The role of radiation therapy for de novo metastatic bladder and renal cancers. Cancer/Radiothérapie, 2024, 28 (1), pp.56 - 65. ⟨10.1016/j.canrad.2023.02.004⟩. ⟨inserm-04517309⟩
• 
  Charlotte Demoor-Goldschmidt, Stéphane Supiot, Marc-André Mahé, Odile Oberlin, Rodrigue Allodji, et al.. Clinical and histological features of second breast cancers following radiotherapy for childhood and young adult malignancy. British Journal of Radiology, 2018, 91 (1086), pp.20170824. ⟨10.1259/bjr.20170824⟩. ⟨inserm-04439735⟩
• 
  Imène Mansouri, Rodrigue S Allodji, Catherine Hill, Chiraz El‐fayech, François Pein, et al.. The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer. European Journal of Heart Failure, 2018, 21 (4), pp.509 - 518. ⟨10.1002/ejhf.1376⟩. ⟨inserm-04439245⟩
• 
  Maria John, Roberto Salgado, Thomas Gevaert, Prudence A Russell, Tom John, et al.. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors. Advances in Anatomic Pathology, 2017, 24 (6), pp.311 - 335. ⟨10.1097/PAP.0000000000000161⟩. ⟨hal-01675236⟩
• 
  Maria John, Roberto Salgado, Thomas Gevaert, Prudence A Russell, Tom John, et al.. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors. Advances in Anatomic Pathology, 2017, 24 (5), pp.235 - 251. ⟨10.1097/PAP.0000000000000162⟩. ⟨hal-01675241⟩
• 
  Manon de Vries-Brilland, Nathalie Rioux-Leclercq, Maxime Meylan, Jonathan Dauvé, Christophe Passot, et al.. Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma. Journal for Immunotherapy of Cancer, 2023, Journal for ImmunoTherapy of Cancer, 11 (11), pp.e006885. ⟨10.1136/jitc-2023-006885⟩. ⟨hal-04341909⟩
• 
  Khalil Saleh, Matthieu Carton, Véronique Dieras, Pierre-Etienne Heudel, Etienne Brain, et al.. Impact of body mass index on overall survival in patients with metastatic breast cancer. The Breast, 2021, 55, pp.16-24. ⟨10.1016/j.breast.2020.11.014⟩. ⟨hal-03345238⟩
• 
  Thomas Grinda, Alison Antoine, William Jacot, Paul-Henri Cottu, Thibault de la Motte Rouge, et al.. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. European Journal of Cancer, 2023, 189, pp.112935. ⟨10.1016/j.ejca.2023.05.023⟩. ⟨hal-04205902⟩
• 
  Alexandre Bertucci, F. Bertucci, Christophe Zemmour, Florence Lerebours, Jean-Yves Pierga, et al.. PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. Frontiers in Oncology, 2020, 10, ⟨10.3389/fonc.2020.575978⟩. ⟨hal-03623650⟩
• 
  C. Robert, A. Munoz, D. Moreau, J. Mazurier, G. Sidorski, et al.. Clinical implementation of deep-learning based auto-contouring tools–Experience of three French radiotherapy centers. Cancer/Radiothérapie, 2021, 25 (6-7), pp.607-616. ⟨10.1016/j.canrad.2021.06.023⟩. ⟨hal-03797764⟩
• 
  Clémence Basse, Antoine Italiano, Nicolas Penel, Olivier Mir, Claire Chemin, et al.. Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years. International Journal of Cancer, 2019, 145 (8), pp.2135-2143. ⟨10.1002/ijc.32307⟩. ⟨hal-02504786⟩
• 
  Fernanda Mosele, Elise Deluche, Amelie Lusque, Loïc Le Bescond, Thomas Filleron, et al.. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nature Medicine, 2023, 29 (8), pp.2110 - 2120. ⟨10.1038/s41591-023-02478-2⟩. ⟨hal-04187928⟩
• 
  D. Dano, A. Lardy-Cleaud, A. Monneur, N. Quenel-Tueux, C. Levy, et al.. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). ESMO Open, 2021, 6 (4), pp.100220. ⟨10.1016/j.esmoop.2021.100220⟩. ⟨hal-03426433⟩

129

177